

European Journal of Immunology

Supporting Information

for

DOI 10.1002/eji.201343593

Rebecca Tadokera, Graeme A. Meintjes, Katalin A. Wilkinson,
Keira H. Skolimowska, Naomi Walker, Jon S. Friedland, Gary Maartens,
Paul T. G. Elkington and Robert J. Wilkinson

**Matrix metalloproteinases and tissue damage
in HIV-tuberculosis immune reconstitution
inflammatory syndrome**

Supporting Table 1

Baseline characteristics of TB-IRIS patients and comparator non-IRIS group

| | TB-IRIS | Non-IRIS | p-value |
|---|---------------------|------------------------|---------|
| n | 22 | 22 | NA |
| Median age (Years, IQR) | 31 (23.2 - 52.7) | 35.75 (22.2 - 54.1) | 0.11 |
| Female n (%) | 68 | 68 | 0.99 |
| Baseline CD4 / μ l, IQR | 62 (14.0 -193.0) | 42.5 (5.0 – 302.0) | 0.17 |
| Median days of TB treatment prior to cART | 56 (13.0 -186.0) | 75.5 (29.0 -173.0) | 0.06 |
| Median days of cART to IRIS or to sample | 14 (5.0 -78.0) | 14 (14 - 14) | 0.94 |
| Previous TB? | 8 (36) | 3 (14) | 0.16 |
| TB disease form n (%) | | | |
| Pulmonary or pleural | 12 (55) | 17 (77) | 0.06 |
| Disseminated | 7 (32) | 4 (18) | 0.51 |
| Pericardial | 1 (4) | - | |
| Lymphadenopathic | 2 (14) | 1 (4) | 0.43 |
| Smear or culture confirmed? | 19 (86) | 13 (59) | 0.045 |

Supporting Table 2: Baseline characteristics of RCT TB-IRIS patients

| | Prednisone treated | Placebo treated | p-value |
|---|--------------------|-----------------|---------|
| n | 16 | 12 | NA |
| Female n (%) | 10 (63) | 5 (42) | 0.45 |
| Baseline CD4/ μ L | 48 [13-181] | 68.5 [5-156] | 0.67 |
| Median days of TB treatment prior to cART | 67 [22-180] | 30 [13-115] | 0.04 |
| Median days of cART to IRIS onset | 14 [5-23] | 7 [3-32] | 0.08 |
| Previous TB? (%) | 3 (19) | 2 (17) | 1.00 |
| Basis of TB Diagnosis | | | |
| Culture confirmed | 9 | 8 | 0.71 |
| Smear only | 4 | 2 | 0.67 |
| Empiric | 3 | 2 | 1.00 |
| TB Disease Form | | | |
| Pulmonary only | 9 | 4 | 0.28 |
| Extrapulmonary | 7 | 8 | 0.44 |
| IRIS manifestation n (%) | | | |
| New Lymph nodes | 6 (38) | 3 (25) | 0.69 |
| New Abscess | 0 | 0 | - |
| New Pulmonary Infiltrates | 3 (19) | 3 (25) | 1.00 |
| New Effusions | 1 (6) | 3 (25) | 0.29 |
| Recurrent Symptoms | 16 (100) | 12(100) | 1.00 |